Efficacy and safety of Maraviroc vs. Efavirenz in treatment-naive patients with HIV-1: 5-year findings

AIDS

Volumn 28, Issue 5, 2014, Pages 717-725

  Cooper, David A ^a   Heera, Jayvant ^b   Ive, Prudence ^c   Botes, Mariette ^d   Dejesus, Edwin ^e   Burnside, Robert ^b   Clumeck, Nathan ^f   Walmsley, Sharon ^g   Lazzarin, Adriano ^h   Mukwaya, Geoffrey ^b   Saag, Michael ⁱ   Van Der Ryst, Elna ^j  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PFIZER INC   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d Private Practice   (South Africa)

^e ORLANDO IMMUNOLOGY CENTER   (United States)

^f SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY OF TORONTO   (Canada)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

more..

Author keywords

Antiretroviral therapy; Efavirenz; HIV 1; Long term; Maraviroc; Randomized controlled trial; Treatment naive

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFECTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEOPLASM; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT RESPONSE; VIRUS LOAD; VOMITING; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD; YOUNG ADULT;

EID: 84898755496     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000131     Document Type: Article

References (31)

1. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-4732.
2. ViiV Healthcare. Celsentri (maraviroc) summary of product characteristics. http://www.viivhealthcare.com/products/selzentry-celsentri. aspx#. [Accessed 3 April 2013]
3. ViiV Healthcare. Selzentry (maraviroc) prescribing information. http://www.viivhealthcare.com/-/media/Files/G/GlaxoSmithKline-Plc/pdfs/ us-selzentry.pdf. [Accessed 3 April 2013]
4. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, DeJesus E, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviralnaive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-813.
5. Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, et al. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect Dis 2011; 52: 925-928.
6. Sierra-Madero J, Di Perri G, Wood R, Saag M, Frank I, Craig C, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials 2010; 11: 125-132.
7. Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010; 55: 558-564.
8. Gulick R, Fätkenheuer G, Burnside R, Hardy D, Nelson M, Portsmouth S, et al. Five-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients. Poster TUPE029 presented at the XIX International AIDS Conference, Washington, DC, USA, 22-27 July 2012.
9. Wasmuth JC, Rockstroh JK, Hardy WD. Drug safety evaluation of maraviroc for the treatment of HIV infection. Expert Opin Drug Saf 2012; 11: 161-174.
10. Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008; 52: 858-865.
11. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196: 304-312.
12. Tsibris AM, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, et al. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis 2009; 48: 642-649.
13. Fry J. FDA/FCHR collaborative public meeting on long-term safety concerns associated with CCR5 antagonist development. http://www.fda.gov/ohrms/dockets/ ac/07/briefing/2007-4283b1-02-03-FDA-draftreport.pdf. [Accessed 3 April 2013]
14. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15: 241-243.
15. Ayoub A, Alston S, Goodrich J, Heera J, Hoepelman AI, Lalezari J, et al. Hepatic safety and tolerability in the maraviroc clinical development program. AIDS 2010; 24: 2743-2750.
16. Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 2012; 28: 437-446.
17. Arribas JR, Pozniak AL, Gallant JE, DeJesus E, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47: 74-78.
18. Rockstroh JK, Lennox JL, DeJesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53: 807-816.
19. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007; 8: 164-172.
20. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-1441.
21. Wilkin TJ, Ribaudo HR, Tenorio AR, Gulick RM. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIVinfected patients. HIV Clin Trials 2010; 11: 351-358.
22. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203: 35-40.
23. Lim JK, Louie CY, Glaser C, Jean C, Johnson B, McDermott DH, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197: 262-265.
24. Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O, et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008; 198: 500-507.
25. Pokorny V, McQueen F, Yeoman S, Merriman M, Merriman A, Harrison A, et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 487-490.
26. Goulding C, McManus R, Murphy A, MacDonald G, Barrett S, Crowe J, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54: 1157-1161.
27. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127: 882-890.
28. Dean M, Jacobson LP, McFarlane G, Margolick JB, Jenkins FJ, Howard OM, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999; 59: 3561-3564.
29. Meyer L, Magierowska M, Hubert JB, Mayaux MJ, Misrahi M, Le Chenadec J, et al. CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups. J Infect Dis 1999; 180: 920-924.
30. Ashton LJ, Stewart GJ, Biti R, Law M, Cooper DA, Kaldor JM. Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens. HIV Med2002; 3: 91-96.
31. Moreno C, Gustot T, Nicaise C, Quertinmont E, Nagy N, Parmentier M, et al. CCR5 deficiency exacerbates T-cellmediated hepatitis in mice. Hepatology 2005; 42: 854-862.